Leading-edge Alzheimer’s disease dementia biomarker testing
"These biomarkers are changing neurodegenerative clinical trials, making it simpler and faster to identify and stratify patients. Through these innovations, research teams can increase the number of patients successfully recruited and also potentially lower the cost of clinical trials. We’re excited to provide testing that opens up new options to support Alzheimer's disease clinical trials.”
Alicia Algeciras-Schimnich, Ph.D., Professor of Laboratory Medicine and Pathology and Co-Director of the Clinical Immunoassay Laboratory at Mayo Clinic Laboratories
The leading edge of biomarker testing
Our physician scientists are actively engaged in research into new Alzheimer’s disease-related biomarkers and attuned to emerging research trends about the impact of neurodegenerative biomarker testing in order to develop the most clinically meaningful assays for both commercial and research purposes.
Among fluid-based biomarkers known to predict Aβ pathology, phosphorylated Tau 217 (p-Tau217) exhibits the highest levels of diagnostic accuracy. Ongoing research continues to clarify the role of additional biomarkers, including neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), in advancing the understanding of neurodegenerative disorders.
Unmatched diagnostic accuracy for detecting Aβ pathology
Mayo Clinic Laboratories’ plasma biomarker testing uses the clinically supported p-Tau217 protein to identify Aβ pathology. Research has revealed that p-Tau217 exhibits high diagnostic accuracy in predicting Aβ positivity.
Using two cutpoints enables increased sensitivity and specificity and overall greater accuracy than single cutpoint testing.
Collaborate with us
Addressing patient needs is at the center of what we do at Mayo Clinic Laboratories BioPharma Diagnostics, and our ties to Mayo Clinic physicians and scientists lend expert clinical leadership to every research project. Our team of medical, laboratory, and business professionals brings unmatched experience to support even the most complex projects. Working side-by-side with partners, we provide direct collaboration with our scientific and medical experts to help you achieve your research goals. Please get in touch — we look forward to discussing testing needs that support your neurodegenerative research program.
Resources
Clinical trials at Mayo Clinic utilizing fluid-based biomarkers (representative sampling)
Please visit our Clinical Trials page to find the full, current list of Alzheimer’s disease and dementia research studies underway at Mayo Clinic.